Indole-Based Compounds as Promising Inhibitors of SARS-CoV-2

  • Anqi Sun The College of Post and Telecommunication, Wuhan Institute of Technology
DOI: https://doi.org/10.18686/aem.v11i4.250
Keywords: Indole, Protease, Inhibitor, SARS-CoV-2

Abstract

This review focused on the recent development of indole-based compounds as anti- SARS-CoV-2 agents with focus on the following objectives: 1) present the design strategy of indole-based compounds as promising inhibitors; 2) focus on recent developments of indole-based compounds and their anti-severe acute respiratory syndrome  coronavirus 2 and anti-severe acute respiratory syndrome coronavirus  activities; 3) summarize molecular docking and the structure–activity relationship, in hopes to inspire the development of new and more creative approaches; and 4) offer perspectives on how indole scaffolds might be exploited in the future.

References

[1] A. Kumar, S. Loharch, S. Kumar, R. P. Ringe, R. Parkesh, Exploiting cheminformatic and machine learning to navigate the available chemical space of potential small molecule inhibitors of SARS-CoV-2, Comput. Struct. Biotec. 19 (2021) 424-438.

[2] G. Culletta, M. R. Gulotta, U. Perricone, A. M. Almerico, M. Tutone, Exploring the SARS-CoV-2 proteome in the search of potential inhibitors via structure-based pharmacophore modeling/docking approach, Computation 8 (2020) 77.

[3] W. Dai, B. Zhang, X. M. Jiang, H. Su, J. Li, Y. Zhao, X. Xie, Z. Jin, J. Peng, F. Liu, Structure-based design of antiviral drug candidates targeting the SARS-CoV-2 main protease, Science 368 (2020) 1-5.

[4] S. Singhal, P. Khanna, L. Khanna, Synthesis, comparative in vitro antibacterial, antioxidant and UV fluorescence studies of bis indole schiff bases and molecular docking with ct-DNA and SARS-CoV-2 M-pro, Luminescence 5 (2021) 1-13.

[5] B. G. Vijayakumar, D. Ramesh, A. Joji, J. J. Prakasan, T. Kannan, In silico pharmacokinetic and molecular docking studies of natural flavonoids and synthetic indole chalcones against essential proteins of SARS-CoV-2, Eur. J. Pharmacol. 886 (2020) 1-11.
Published
2023-03-02
Issue
Vol 11, No 4 (2022)
Section
Original Research Article

Copyright (c) 2023 Anqi Sun

Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.

Authors submitting to USP journals agree to publish their manuscript under the Creative Commons Attribution-NonCommercial 4.0 International License (CC BY-NC 4.0) where authors agree to allow third parties to share their work (copy, distribute, transmit) and to adapt it, under the condition that the authors are given credit, and that in the event of reuse or distribution, the terms of this license are made clear

Authors retain copyright of their work, with first publication rights (online and print) granted to Universe Scientific Publishing or the owner of the journal in question.